Short answer: Retatrutide, also known by the development code LY3437943, is an investigational peptide candidate designed as a single-molecule agonist of three hormone receptors: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon. As of July 2026, it remains under clinical investigation and has not been approved by the U.S. Food and Drug Administration or any other regulatory agency.

What is retatrutide?

Retatrutide is a synthetic peptide being studied for its ability to activate the GIP, GLP-1, and glucagon receptors. Because it engages three receptor systems in one molecule, researchers describe it as a triple hormone receptor agonist or triple agonist.

The identifier LY3437943 is the development code used in scientific literature and trial registries. Retatrutide is not the same compound as semaglutide or tirzepatide. Semaglutide targets the GLP-1 receptor, while tirzepatide targets GIP and GLP-1 receptors. Retatrutide adds glucagon-receptor activity to GIP and GLP-1 receptor activity.

How does retatrutide's triple-agonist mechanism work?

Each receptor in retatrutide's design participates in metabolic signaling:

• GIP receptor: GIP is an incretin hormone involved in nutrient-responsive signaling and insulin secretion.

• GLP-1 receptor: GLP-1 signaling is involved in glucose-dependent insulin secretion, glucagon regulation, gastric emptying, and appetite-related pathways.

• Glucagon receptor: Glucagon signaling participates in hepatic glucose production, lipid metabolism, and energy-expenditure pathways.

Researchers are studying whether coordinated activity at these three receptors produces effects that differ from single- or dual-receptor agonism. Receptor activation does not by itself establish safety, efficacy, or an approved medical use; those questions require controlled clinical trials and regulatory review.

Is “GLP-3” an accurate name for retatrutide?

No. “GLP-3” is an informal media nickname, not a recognized hormone or scientific drug class. Retatrutide does not activate a receptor called GLP-3. The accurate description is a GIP, GLP-1, and glucagon receptor triple agonist.

What has research reported so far?

A randomized, double-blind, placebo-controlled Phase 2 trial published in the New England Journal of Medicine in 2023 enrolled 338 adults with obesity or overweight plus a weight-related condition, without type 2 diabetes. The investigators reported dose-dependent changes in body weight over 48 weeks and evaluated safety and adverse events. Gastrointestinal adverse events were the most frequently reported events and were generally associated with dose escalation. The study was sponsored by Eli Lilly.

Phase 2 findings are evidence from a controlled study, but they are not the same as regulatory approval and do not establish that an investigational compound is appropriate for use outside a trial.

What is retatrutide's research status in 2026?

Eli Lilly reported topline Phase 3 results from the TRIUMPH-1 study in May 2026 and additional Phase 3 data in June 2026. ClinicalTrials.gov also lists ongoing or completed studies across obesity, type 2 diabetes, cardiovascular and renal outcomes, sleep apnea, osteoarthritis pain, and metabolic liver disease. The questions, participants, endpoints, and status differ by study, so each registry record should be reviewed individually.

These announcements do not mean retatrutide is approved. As of July 2026, Lilly states that retatrutide is investigational, not available for public use, and available to human participants only through Lilly-sponsored clinical trials.

Is retatrutide FDA approved?

No. Retatrutide has not been approved by the FDA or any other regulatory agency. It should not be presented as an approved medicine, a substitute for an approved therapy, or a product for personal use. No claim about an expected approval date should be treated as certain unless it comes from a regulator.

How is retatrutide different from semaglutide and tirzepatide?

The clearest distinction is receptor pharmacology:

• Semaglutide: GLP-1 receptor agonist.

• Tirzepatide: GIP and GLP-1 receptor agonist.

• Retatrutide: GIP, GLP-1, and glucagon receptor agonist.

This mechanistic comparison should not be read as a recommendation or as proof that one compound is safer or more effective than another. Reliable comparisons require appropriately designed head-to-head research.

Why is retatrutide studied in laboratories?

Laboratory researchers may use reference or research materials to study identity, purity, stability, analytical methods, receptor pharmacology, or other preclinical questions. Responsible sourcing depends on documentation and traceability, including a lot-specific certificate of analysis, stated analytical methods, storage information, and clear labeling.

A certificate of analysis documents tests performed on a specific lot; it is not evidence of regulatory approval or suitability for human or veterinary use. PepMarket's materials are labeled for laboratory research only. Researchers can review the Retatrutide compound profile (/research-library/compound/retatrutide) and the Retatrutide research compound page (/product/6a4eb27a4ef90cd30a9c5378) for compound data and available lot documentation.

Common questions about retatrutide

What does LY3437943 mean?

LY3437943 is the development code used for retatrutide in scientific publications and clinical-trial records.

Is retatrutide a peptide?

Yes. Retatrutide is a synthetic peptide engineered to act at GIP, GLP-1, and glucagon receptors.

Can retatrutide be used outside a clinical trial?

Retatrutide is not approved for public use. Lilly states that human access is limited to its clinical trials. PepMarket products are strictly for laboratory research and are not for human or veterinary use.

Where can researchers verify current trial information?

ClinicalTrials.gov and peer-reviewed journal publications are primary places to verify trial design, enrollment, status, and results. Because study records change, researchers should confirm the “last update posted” date on each registry entry.

Primary sources and further reading

• Eli Lilly: What to know about retatrutide (https://www.lilly.com/news/stories/what-to-know-about-retatrutide), current investigational status and mechanism.

• ClinicalTrials.gov: TRIUMPH-3, NCT05882045 (https://clinicaltrials.gov/study/NCT05882045), an official study registry record.

• Jastreboff et al., NEJM (2023), DOI 10.1056/NEJMoa2301972 (https://www.nejm.org/doi/full/10.1056/NEJMoa2301972), peer-reviewed Phase 2 obesity trial.

• Eli Lilly: TRIUMPH-1 topline Phase 3 announcement, May 21, 2026 (https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss).

Research-use disclaimer: This page is educational and intended for laboratory researchers. It is not medical advice and does not provide dosing, administration, or treatment guidance. Retatrutide remains investigational and is not approved for human or veterinary use.